Revolution Medicines, Inc. Common Stock
RVMD
$190.27
+0.82%
Revolution Medicines, Inc. is a clinical-stage precision oncology company developing novel small-molecule therapies that bind directly to RAS variants, including its RAS(ON) inhibitor platform, with a lead asset (daraxonrasib) targeting RAS-addicted cancers such as pancreatic, colorectal, and lung tumors. The company occupies a differentiated position as a structure-based drug discovery specialist attacking the historically undruggable RAS pathway, a franchise that has attracted intense strategic interest from large-cap oncology players facing patent cliffs. The investor narrative has been transformed by a Phase 3 pancreatic cancer trial that reportedly doubled survival versus chemotherapy and a rapid FDA approval for Rasonque roughly one month after filing, with analysts citing approximately $11.5 billion in peak sales potential. That clinical and regulatory momentum drove a multi-fold share price surge in 2026, supported by a $2.2 billion upsized equity raise, and the debate now centers on whether the commercial opportunity is already priced in after the stock's dramatic re-rating.…
RVMD
Revolution Medicines, Inc. Common Stock
$190.27
Related headlines
RVMD 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $258.84 and implied upside of +36.0% versus the current price.
Average Target
$258.84
0 analysts
Implied Upside
+36.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$179 - $320
Analyst target range
Coverage is robust, with 24 analysts and a consensus recommendation of strong buy (mean rating 1.28 on a 1-to-5 scale where 1 is a strong buy). The average target price is $258.84, implying roughly +38.4% upside from the current $186.99, and the consensus leans decisively bullish. Recent institutional ratings show a wall of reiterations rather than fresh upgrades: BofA Securities, Stifel, Needham, Guggenheim, and UBS all maintained Buy ratings between late August and late September 2026, while Evercore ISI, Wedbush, Oppenheimer, RBC Capital, and Truist maintained Outperform or Buy, indicating conviction has been stable post-approval.
The target range is wide, from a low of $179.00 (essentially at the current price, implying no upside) to a high of $320.00 (roughly +71% upside), a spread of about 79% of the low end that signals meaningful disagreement about the commercial trajectory. The high target likely assumes rapid Rasonque uptake, expansion into additional RAS-driven indications, and multiple expansion on peak-sales estimates near $11.5 billion, while the low target effectively prices in launch execution risk, competition, or a more conservative revenue ramp. The consensus revenue estimate range of $3.84 billion to $14.53 billion and EPS range of $4.74 to $30.62 reinforce that uncertainty; the tight clustering of ratings at Buy/Outperform with no recent downgrades suggests strong conviction in the platform, but the wide price targets mean position sizing should account for binary clinical and commercial risk.
Drowning in data?
Find the real signal!
Bulls vs Bears: RVMD Investment Factors
The bull case rests on hard, verifiable catalysts — a Phase 3 pancreatic trial that doubled survival, an FDA approval one month after filing, a strong buy consensus with +38.4% average upside, and a fortress balance sheet with $18.67 cash per share — while the bear case rests on the price already reflecting much of that success. The evidence currently favors the bulls on fundamentals but the bears on near-term risk/reward: the stock has delivered +249.9% in a year, momentum has flatlined (-1.97% over one month), and it trades at 9.28x book with no revenue to anchor valuation. The single most important tension is the Rasonque commercial launch trajectory — if early scripts validate the $8.16 billion average revenue estimate, the forward EPS of $15.21 becomes credible and the stock is cheap; if uptake lags, there is no valuation floor given the absence of any revenue or earnings multiple. Investors are effectively paying today for a launch that has not yet reported a single dollar of product revenue.
Bullish
- Phase 3 data doubled pancreatic survival: Daraxonrasib reportedly doubled survival versus chemotherapy in a Phase 3 pancreatic cancer trial, a result that could redefine the standard of care in one of oncology's deadliest indications. This is the single largest value driver behind the stock's +249.9% one-year move and underpins analyst peak-sales estimates of roughly $11.5 billion.
- FDA approval one month after filing: Rasonque won FDA approval roughly one month after filing, an unusually rapid regulatory path that validates both the clinical package and the company's execution. This de-risks the regulatory leg of the thesis and shifts the debate from 'will it be approved' to 'how fast can it commercialize.'
- Strong buy consensus with 38% upside: All 24 covering analysts carry a mean rating of 1.28 (strong buy) with an average target of $258.84, implying +38.4% upside from $186.99. The high target of $320.00 implies roughly +71%, and there have been no recent downgrades — BofA, Stifel, Needham, Guggenheim and UBS all reiterated Buy between late August and late September 2026.
- Fortress balance sheet after $2.2B raise: Debt-to-equity is just 0.097 and the current ratio is 7.14, with $18.67 of cash per share following the $2.2 billion upsized equity offering that generated $2.66 billion in net financing cash flow in Q2 2026. This funds launch and pipeline expansion without near-term financing risk, a rarity among pre-revenue biotechs.
Bearish
- Losses nearly tripled year over year: Q2 2026 net income was -$644.4 million (-$3.06 EPS) versus -$247.8 million (-$1.31) in Q2 2025, with R&D up to $394.9 million from $224.1 million and SG&A up to $110.2 million from $40.6 million. Trailing twelve-month free cash flow is -$1.59 billion, and the burn is accelerating as launch preparation scales.
- Valuation embeds flawless execution: At 9.28x book — near the top of its historical 2.16x to 15.15x range — and with a forward PE of -32.35 against consensus EPS of $15.21, the market is discounting years of successful commercialization. There is no revenue denominator (PS of 0, gross margin 0%), so there is no fundamental valuation floor if the launch disappoints.
- Momentum has stalled post-catalyst: The 1-month change is -1.97% and the 3-month change is -1.18%, with relative strength versus SPY at -0.95 and -4.03 respectively, despite a +249.9% one-year gain. The stock is 16.6% below its $224.31 high and consolidating, a classic post-catalyst digestion pattern that suggests the easy money has been made.
- Wide analyst dispersion signals uncertainty: Targets range from $179.00 (essentially zero upside) to $320.00, a spread of about 79% of the low end, while revenue estimates span $3.84 billion to $14.53 billion and EPS estimates $4.74 to $30.62. That dispersion reflects genuine disagreement about launch trajectory, not just noise.
RVMD Technical Analysis
RVMD is in a powerful, sustained uptrend, with a 1-year price change of +249.9% versus the S&P 500's +13.1%, translating to relative strength of +236.8 percentage points over twelve months. At the current price of $186.99, the stock sits at roughly 78% of its 52-week range of $53.665 to $224.31, meaning it is trading in the upper quartile but about 16.6% below its high. This positioning reflects a stock that has already delivered the bulk of a massive re-rating and is now consolidating rather than breaking to new highs, a pattern typical of post-catalyst digestion in high-beta biotech.
Short-term momentum has clearly decelerated: the 1-month change is -1.97% and the 3-month change is -1.18%, both sharply diverging from the +249.9% one-year gain and the +38.2% six-month gain. Relative strength versus SPY is negative over both 1 month (-0.95) and 3 months (-4.03), confirming the stock is now lagging the market after a period of extreme outperformance. This divergence signals mean reversion and profit-taking following the August peak near $224, rather than a confirmed trend reversal, since the 6-month relative strength remains strongly positive at +31.75. Volume of roughly 1.72 million shares and a short ratio of 5.9 suggest moderate short interest that could amplify moves in either direction.
Key technical support sits at the 52-week low of $53.665, with a more relevant near-term floor around the $178-188 zone where the stock has repeatedly found buyers in October, including the $177.96 close on October 16. Resistance is defined by the 52-week high of $224.31; a breakout above that level would confirm resumption of the primary uptrend and likely trigger momentum-driven buying, while a breakdown below the $178 area would open the door to a deeper retracement toward the $150s. With a beta of 1.401, the stock is roughly 40% more volatile than the market, and a maximum drawdown of -24.95% underscores the position-sizing risk; a 1.4 beta means investors should size positions meaningfully smaller than a market-equivalent allocation.
Beta
1.40
1.40x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$57-$224
Price range past year
Annual Return
+227.9%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | -6.9% | +0.7% |
| 3m | +1.5% | +3.0% |
| 6m | +36.4% | +6.8% |
| 1y | +227.9% | +11.9% |
| ytd | +140.8% | +12.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
Revolution Medicines is pre-revenue, with reported revenue of $0 in the most recent quarter (Q2 2026) and $0 across every quarter in the provided income statement history; the only revenue line item in the segment data is a $7.014 million collaboration revenue figure from a prior period. The growth trajectory is therefore not measurable through a traditional revenue lens, and the investment case rests entirely on pipeline value: the Phase 3 pancreatic data and the Rasonque approval are the catalysts that analysts expect to convert into roughly $8.16 billion in average estimated revenue (range $3.84 billion to $14.53 billion). Until commercialization ramps, the absence of a revenue base means the stock trades on probability-weighted peak sales rather than current fundamentals.
Profitability is deeply negative and worsening as the company scales its late-stage development and launch preparation. Q2 2026 net income was -$644.4 million with EPS of -$3.06, compared with -$453.8 million (-$2.29) in Q1 2026 and -$247.8 million (-$1.31) in Q2 2025, reflecting a near-tripling of quarterly losses year over year. Research and development expense rose to $394.9 million in Q2 2026 from $224.1 million a year earlier, while selling, general and administrative costs climbed to $110.2 million from $40.6 million, consistent with pre-launch commercialization build-out. Gross margin is reported as 0% (no product revenue), and the operating margin of 0% in the ratio data reflects the absence of a revenue denominator rather than operational break-even.
The balance sheet is the company's key strength: debt-to-equity is just 0.097, the current ratio is 7.14, and cash per share stood at $18.67 as of Q2 2026, following the $2.2 billion equity raise that produced $2.66 billion in net financing cash flow during the quarter. However, cash burn is substantial: trailing twelve-month free cash flow is -$1.59 billion, with Q2 2026 operating cash flow of -$741.5 million and free cash flow of -$745.3 million, and cash at period end of $820.3 million. ROE of -69.3% and ROA of -30.1% reflect both the losses and the recent capital infusion, and with a cash-flow-to-debt ratio of -1.16, the company remains dependent on its equity-funded liquidity rather than internal cash generation to finance the launch.
Quarterly Revenue
$0.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-1.6B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Because net income is negative (-$644.4 million in Q2 2026) and EBITDA is also negative (-$620.6 million), neither the trailing PE of -13.39 nor the EV/EBITDA of -13.68 is meaningful, and the PS ratio is reported as 0 given the absence of revenue. The most informative metric is the forward PE of -32.35, which is negative only because trailing earnings remain negative while consensus forward EPS of $15.21 turns positive, implying the market expects a dramatic swing to profitability as Rasonque commercializes. The gap between the negative trailing multiple and the positive forward EPS estimate captures the binary nature of the story: the market is pricing a successful launch well ahead of reported results.
On price-to-book, RVMD trades at 9.28x versus its own recent history, and the absence of positive earnings or sales makes peer multiple comparison unreliable; the valuation data provides no industry average for PE or PS, so a quantified premium or discount to the biotechnology sector cannot be computed from the supplied inputs. What can be said is that a 9.3x book multiple for a pre-revenue biotech embeds substantial intangible pipeline value, and the forward PE of -32.35 versus consensus EPS of $15.21 implies the market is discounting earnings several years out. The premium is justified only if daraxonrasib achieves the roughly $11.5 billion peak sales analysts cite and the $8.16 billion average revenue estimate materializes.
Historically, RVMD's price-to-book ratio has ranged from about 2.16x (Q1 2023) to 15.15x (Q2 2026), and the current 9.28x sits in the upper portion of that band but below the Q2 2026 peak. The price-to-free-cash-flow ratio of -16.87 and price-to-operating-cash-flow of roughly -53x reflect persistent cash burn rather than a valuation floor. Trading near the top of its own historical book-value band signals that the market is pricing in optimistic launch expectations, leaving limited margin of safety if clinical or commercial execution disappoints.
PE
-13.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by an accelerating cash burn against a still-zero revenue base. Q2 2026 operating cash flow was -$741.5 million and free cash flow -$745.3 million, with trailing twelve-month FCF of -$1.59 billion, while period-end cash stood at $820.3 million — meaning the company is burning roughly its entire cash balance every quarter at the current rate. Losses are widening fast: net income of -$644.4 million in Q2 2026 versus -$247.8 million a year earlier, with R&D at $394.9 million and SG&A at $110.2 million reflecting launch build-out. The balance sheet is strong (debt-to-equity 0.097, current ratio 7.14, $18.67 cash per share after the $2.2 billion raise), but the cash-flow-to-debt ratio of -1.16 confirms the company depends entirely on equity-funded liquidity rather than internal generation, leaving it exposed to capital-market conditions for any future raise.
Market and competitive risks center on valuation compression and binary execution. At 9.28x book — in the upper portion of a historical 2.16x to 15.15x band — and with a forward PE of -32.35 against consensus EPS of $15.21, the stock prices in years of successful commercialization with no margin of safety; PS and gross margin are both 0% because there is no product revenue yet. Beta of 1.401 means the shares are roughly 40% more volatile than the market, so any sector rotation out of high-multiple biotech would be amplified. Recent coverage highlights the tension directly: a Motley Fool piece notes the 5X surge 'may already price in much of the upside,' and another argues the stock carries risks making it 'unsuitable for most investors at current levels,' while competition in RAS-driven oncology and the possibility of a larger player acquiring a rival RAS asset (as Merck's $6.7 billion Terns deal illustrates) could erode the franchise's strategic premium.
In a worst-case scenario, a disappointing first full quarter of Rasonque sales would collide with a valuation that has no revenue or earnings floor, triggering analyst target cuts and a de-rating of peak-sales assumptions. The stock is already 16.6% below its $224.31 high, and the analyst low target of $179.00 sits essentially at the current price — meaning even the most cautious analyst sees no downside cushion, while a retracement to the $178-188 technical support zone would be a modest -5%, and a break below it opens the door to the $150s (roughly -20%). A severe scenario revisiting the 52-week low of $53.665 would represent a -71% loss from $186.99, though that level predates the Phase 3 and approval catalysts; a more realistic adverse case of -25% to -35% (to roughly $122-$140) aligns with the stock's recorded max drawdown of -24.95% and would erase the entire post-approval gain.